FDAsafety guidance77% confidence
FDA AP — LEUPROLIDE ACETATE (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Calcium Acetate; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA075471. Sponsor: MEITHEAL. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: LEUPROLIDE ACETATE.
Supporting Context
- Therapeutic area
- Renal · Phosphate Binder
- Sub-indication
- General
Related signal: FDA Grants AP Status for Calcium Acetate ANDA202420 by Chartwell Molecular